|
|
|
| Clinical Observation of CYP2C9 and VKORC1 Gene Polymorphism Guiding Postoperative Anticoagulant Therapy in Patients with Heart Valve |
| LIN Shengxiong, WU Danna, CAO Yiqiu |
| Hainan Provincial People's Hospital, Hainan Haikou 570311, China |
|
|
|
|
Abstract Objective: To study the clinical value of CYP2C9 and VKORC1 gene polymorphisms in guiding postoperative anticoagulation therapy in patients with heart valves. Methods: A retrospective analysis was performed on AIS patients admitted to our hospital from March 2014 to July 2017. 95 patients undergoing CYP2C9 and VKORC1 gene polymorphism detection were selected as the study group, and 95 patients without detection were selected as the control group. The CYP2C9 and VKORC1 genotypes of the patients in the study group were observed, the warfarin dosage and the international normalized ratio (INR) compliance time of the patients with different genotypes were compared, and the INR compliance time of the study group and the control group were compared. Results: In the study group, 85 patients were of CYP2C9 *1/*1 type, 9 were of CYP2C9 *1/*3 type, 1 was of CYP2C9 *3/*3 type; 77 were of VKORC1 type AA, 18 were of VKORC1 AG type, VKORC1 GG type was not found. In the study group, patients with CYP2C9 *1/*1 type had a higher actual dose of warfarin than CYP2C9 *1/*3 patients, and the time for INR to reach the standard was shorter, and the difference was significant (P<0.05); patients of VKORC1 AA type had lower actual dose of warfarin, compared with VKORC1 AG patients, and the INR compliance time was shorter, and the difference was significant (P<0.05). The study group had shorter INR compliance time than the control group, and the difference was significant (P<0.05). Conclusion: The detection of CYP2C9 and VKORC1 gene polymorphisms in the postoperative anticoagulation therapy of heart valve patients plays an important role in the formulation and adjustment of the initial treatment plan, and can provide an important reference for the early clinical plan formulation.
|
|
|
|
|
|
[1] 王玉庆,董力,石应康,等.汉族人心脏瓣膜置换术后华法林用药剂量与基因型关系的相关性研究[J].中国胸心血管外科临床杂志,2016,23(1):1~6.
[2] 回翔,范晴晴,李丹滢,等.基因指导的华法林剂量预测模型在心脏瓣膜术后早期患者中的验证与评价[J].药学服务与研究,2020,20(4):241~246.
[3] 罗赛赛,郑巧伟,王陶陶,等.心脏瓣膜置换术后影响华法林抗凝达标的相关因素分析[J].药物流行病学杂志,2019,28(8):507~510.
[4] 程弦,白树堂.CYP2C9及APOE基因多态性与华法林稳态剂量和模型预测剂量的相关性研究[J].中国胸心血管外科临床杂志,2019,26(6):543~547.
[5] International Warfarin Pharmacogenetics Consortium,Klein T E,Altman R B,et al.Estimation of the warfarin dose with clinical and pharmacogenetic data[J].N Engl Med,2009,360(8):753~764.
[6] 彭齐,陈晓英,宋杰.CYP2C9及VKORC1基因多态性对心脏瓣膜置换术后华法林个体剂量差异的研究[J].解放军医药杂志,2014,26(12):16~20,27.
[7] Huang S W,Chen H S,Wang X Q,et al.Validation of VKORC1 and CYP2C9 genotypes on interindividual warfa- rin maintenance dose:a prospective study in Chinese pa- tients[J].Pharmacogenet Genomics,2009,19(3):226~234.
[8] 陈幽攸,任小群,杨探,等.基于CYP2C9与VKORC1基因多态性的心脏瓣膜置换术后华法林个体化给药剂量预测的3种模型算法比较[J].国际检验医学杂志,2021,42(4):439~443.
[9] 高菲,宋洪涛,曾志勇,等.CYP2C9和VKORC1基因多态性对心脏瓣膜置换术后华法林维持剂量和抗凝效果的影响[J].中国药房,2010,21(22):2053~2057.
[10] 蒿叶霞,郑璇,胡元萍,等.CYP2C9及VKORC1基因多态性对心脏瓣膜置换术后华法林抗凝治疗策略的影响[J].检验医学,2019,34(2):126~129. |
|
|
|
2022, Vol. 28 
